Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 932040, 13 pages
http://dx.doi.org/10.1155/2013/932040
Research Article

Specific Dioscorea Phytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines

1Department of Food and Nutrition, Providence University, No. 200, Section 7, Taiwan Boulevard, Shalu District, Taichung 43301, Taiwan
2Institute of Agricultural Biotechnology Research Center, Academia Sinica, No. 128, Section 2, Academia Road, Nankang, Taipei 11529, Taiwan

Received 11 January 2013; Revised 27 May 2013; Accepted 3 June 2013

Academic Editor: Télesphore Benoît Nguelefack

Copyright © 2013 Wei-Ting Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Matera, “The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer,” Cancer Treatment Reviews, vol. 36, no. 2, pp. 131–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Chen, P. Wang, S. Chen et al., “Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine,” Cancer Immunology, Immunotherapy, vol. 16, pp. 1989–2002, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. C. G. Drake, “Prostate cancer as a model for tumour immunotherapy,” Nature Reviews Immunology, vol. 10, no. 8, pp. 580–593, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Aarnoudse, J. J. G. Vallejo, E. Saeland, and Y. van Kooyk, “Recognition of tumor glycans by antigen-presenting cells,” Current Opinion in Immunology, vol. 18, no. 1, pp. 105–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Hatfield, A. E. Merrick, E. West et al., “Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy,” Journal of Immunotherapy, vol. 31, no. 7, pp. 620–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. M. Steinman and M. Pope, “Exploiting dendritic cells to improve vaccine efficacy,” The Journal of Clinical Investigation, vol. 109, no. 12, pp. 1519–1526, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Takeda, T. Kaisho, and S. Akira, “Toll-like receptors,” Annual Review of Immunology, vol. 21, pp. 335–376, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Apetoh, F. Ghiringhelli, A. Tesniere et al., “Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy,” Nature Medicine, vol. 13, no. 9, pp. 1050–1059, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Mata-Haro, C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, and T. C. Mitchell, “The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4,” Science, vol. 316, no. 5831, pp. 1628–1632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. P. A. Hopkins, J. D. Fraser, A. C. Pridmore, H. H. Russell, R. C. Read, and S. Sriskandan, “Superantigen recognition by HLA class II on monocytes up-regulates toll-like receptor 4 and enhances proinflammatory responses to endotoxin,” Blood, vol. 105, no. 9, pp. 3655–3662, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Tsukamoto, K. Fukudome, S. Takao et al., “Multiple potential regulatory sites of TLR4 activation induced by LPS as revealed by novel inhibitory human TLR4 mAbs,” International Immunology, vol. 24, no. 8, pp. 495–506, 2012. View at Google Scholar
  12. K. Breckpot and D. Escors, “Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification,” Endocrine, Metabolic and Immune Disorders, vol. 9, no. 4, pp. 328–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. W. Dubensky Jr. and S. G. Reed, “Adjuvants for cancer vaccines,” Seminars in Immunology, vol. 22, no. 3, pp. 155–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Shanmugam, S. Rajoria, A. L. George, A. Mittelman, R. Suriano, and R. K. Tiwari, “Synthetic toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants,” PLoS ONE, vol. 7, no. 2, Article ID e30839, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. O. Akoruda, “Genetic improvement of vegetable crops: yam (Dioscorea spp.),” in Genetic Improvement of Vegetable Crops, M. Kasloo, Ed., pp. 717–733, Pergamon Press, Elmsford, NY, USA, 1984. View at Google Scholar
  16. S. Y. Liu, J. Y. Wang, Y. T. Shyu, and L. M. Song, “Studies on yam (Dioscorea spp.) in Taiwan,” The Journal of Chinese Medicine, vol. 6, pp. 111–126, 1995. View at Google Scholar
  17. M. L. Ho, Y. S. Hsieh, J. Y. Chen et al., “Antimetastatic potentials of Dioscorea nipponica on Melanoma in vitro and in vivo,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 507920, 13 pages, 2011. View at Publisher · View at Google Scholar
  18. T. B. Nguelefack, M. Mbiantcha, A. Kamanyi, R. B. Teponno, A. L. Tapondjou, and P. Watcho, “Analgesic and anti-inflammatory properties of extracts from the bulbils of Dioscorea bulbifera L. var sativa (Dioscoreaceae) in mice and rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 912935, 9 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Wu, K. Peng, L. Horng, H. Sung, and H. Huang, “Antiosteoporotic activity of Dioscorea alata L. cv. phyto through driving mesenchymal stem cells differentiation for bone formation,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 712892, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Fu, Y. Hsu, P. Lee et al., “Dioscorin isolated from Dioscorea alata activates TLR4-signaling pathways and induces cytokine expression in macrophages,” Biochemical and Biophysical Research Communications, vol. 339, no. 1, pp. 137–144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Liu, F. Yang, C. P. Lu et al., “Polysaccharides from Dioscorea batatas induce tumor necrosis factor-α secretion via Toll-like receptor 4-mediated protein kinase signaling pathways,” Journal of Agricultural and Food Chemistry, vol. 56, no. 21, pp. 9892–9898, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. P. F. Su, C. J. Li, C. C. Hsu et al., “Dioscorea phytocompounds enhance murine splenocyte proliferation ex vivo and improve regeneration of bone marrow cells in vivo,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 731308, 11 pages, 2011. View at Publisher · View at Google Scholar
  23. S. Yin, C. Wang, and N. Yang, “Interleukin-4 enhances trafficking and functional activities of GM-CSF-stimulated mouse myeloid-derived dendritic cells at late differentiation stage,” Experimental Cell Research, vol. 317, no. 15, pp. 2210–2221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. K. D. Pavelko, K. L. Heckman, M. J. Hansen, and L. R. Pease, “An effective vaccine strategy protective against antigenically distinct tumor variants,” Cancer Research, vol. 68, no. 7, pp. 2471–2478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Y. Jung, M. H. Son, S. H. Kim, D. Cho, and T. S. Kim, “IL-32γ induces the maturation of dendritic cells with Th1- and Th17-polarizing ability through enhanced IL-12 and IL-6 production,” Journal of Immunology, vol. 186, no. 12, pp. 6848–6859, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. F. Lai, C. F. Li, and C. Y. Li, “Characterization and thermal behavior of six sulphated polysaccharides from seaweeds,” Food Hydrocolloids, vol. 8, no. 3-4, pp. 215–232, 1994. View at Google Scholar
  27. J. Youn, S. Nagaraj, M. Collazo, and D. I. Gabrilovich, “Subsets of myeloid-derived suppressor cells in tumor-bearing mice,” Journal of Immunology, vol. 181, no. 8, pp. 5791–5802, 2008. View at Google Scholar · View at Scopus
  28. E. Meylan, J. Tschopp, and M. Karin, “Intracellular pattern recognition receptors in the host response,” Nature, vol. 442, no. 7098, pp. 39–44, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Pan, G. X. Wang, B. Yin et al., “Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function,” Blood, vol. 111, no. 1, pp. 219–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Boissier, E. Assier, G. Falgarone, and N. Bessis, “Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm,” Joint Bone Spine, vol. 75, no. 4, pp. 373–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Larmonier, M. Marron, Y. Zeng et al., “Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10,” Cancer Immunology, Immunotherapy, vol. 56, no. 1, pp. 48–59, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Morse, J. R. Hall, and J. M. D. Plate, “Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer,” Expert Opinion on Biological Therapy, vol. 9, no. 3, pp. 331–339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Tosolini, A. Kirilovsky, B. Mlecnik et al., “Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer,” Cancer Research, vol. 71, no. 4, pp. 1263–1271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Guo, G. Wei, J. Zhu et al., “IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 32, pp. 13463–13468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity,” Nature Reviews Immunology, vol. 3, no. 2, pp. 133–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Nishimura, M. Nakui, M. Sato et al., “The critical role of Th1-dominant immunity in tumor immunology,” Cancer Chemotherapy and Pharmacology, vol. 46, pp. S52–S61, 2000. View at Google Scholar · View at Scopus
  37. P. Muranski, A. Boni, P. A. Antony et al., “Tumor-specific Th17-polarized cells eradicate large established Melanoma,” Blood, vol. 112, no. 2, pp. 362–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. L. Gnerlich, J. B. Mitchem, J. S. Weir et al., “Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer,” Journal of Immunology, vol. 185, no. 7, pp. 4063–4071, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. O. A. W. Haabeth, K. B. Lorvik, C. Hammarström et al., “Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer,” Nature Communications, vol. 2, no. 1, article A240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Yamamoto, T. Kamigaki, K. Yamashita et al., “Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer,” Oncology Reports, vol. 22, no. 2, pp. 337–343, 2009. View at Publisher · View at Google Scholar · View at Scopus